The Carroll Center for the Blind, in partnership with Alkeus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for serious retinal diseases, invites you to a free webinar designed to educate individuals on the advancing research they have done for Stargardt’s Disease. This special webinar offers a unique opportunity to learn about the latest advancements in Stargardt disease research, hear from an expert developing potential new treatments, and engage directly with the Alkeus team in a welcoming and accessible environment.

Event Details

Date: Thursday, May 14, 2026

Time: 11:00 a.m. – 12:00 p.m. EST

Location: Zoom (link provided upon registration)

Speaker: Dr. Carlos Quezada-Ruiz, Chief Medical Officer at Alkeus

This session will explore Alkeus’ groundbreaking work, with insights from chief medical officer Carlos Quezada-Ruiz and a focus on NORTHSTAR, a Phase 3 clinical trial evaluating gildeuretinol for individuals with Stargardt disease.

What You’ll Learn

• How Stargardt disease affects the retina and vision
• Today’s evolving research landscape
• How gildeuretinol is designed to work
• The NORTHSTAR clinical trial, including its goals and study design
• The experience of an individual with Stargardt disease

Whether you are personally affected, supporting a loved one, or simply interested in the future of retinal research, we invite you to join this important conversation. This is a valuable opportunity to hear firsthand what participation in a clinical trial might be like and how research studies like NORTHSTAR are shaping the future of care, directly from Alkeus’ Chief Medical Officer.

This webinar will be recorded and made available on our YouTube channel after the event. Make sure to subscribe to receive a notification when the recording is available!

About the Speaker

Dr. Carlos Quezada-Ruiz is a retina specialist with over 15 years of clinical experience and leadership in drug development, currently serving as Chief Medical Officer at Alkeus and previously at Genentech/Roche and 4D Molecular Therapeutics. He has contributed to breakthrough therapies, including Vabysmo, SUSVIMO, and gene therapies, and has led multiple regulatory filings resulting in approvals in the retina field. He has authored more than 40 scientific publications and remains active in research, teaching, and global collaboration. Dr. Quezada-Ruiz has served on the scientific committee of the Mexican Retina Society and the editorial board of the Mexican Journal of Ophthalmology, and is a Fellow of the American Society of Retina Specialists (ASRS) and a member of AAO, ARVO, EURETINA, PAAO, AMR, SMO, and ACOREV. His honors include the ASRS Senior Honor Award, the Roche Award of Excellence, and Genentech’s Medical Excellence Award.

Contact Information

If you have any questions or need help registering, please email development@car​roll.org or call (617) 969-6200 ext 236.